PPARγ in Ischemia-Reperfusion Injury: Overview of the Biology and Therapy
- PMID: 33995008
- PMCID: PMC8117354
- DOI: 10.3389/fphar.2021.600618
PPARγ in Ischemia-Reperfusion Injury: Overview of the Biology and Therapy
Abstract
Ischemia-reperfusion injury (IRI) is a complex pathophysiological process that is often characterized as a blood circulation disorder caused due to various factors (such as traumatic shock, surgery, organ transplantation, burn, and thrombus). Severe metabolic dysregulation and tissue structure destruction are observed upon restoration of blood flow to the ischemic tissue. Theoretically, IRI can occur in various tissues and organs, including the kidney, liver, myocardium, and brain, among others. The advances made in research regarding restoring tissue perfusion in ischemic areas have been inadequate with regard to decreasing the mortality and infarct size associated with IRI. Hence, the clinical treatment of patients with severe IRI remains a thorny issue. Peroxisome proliferator-activated receptor γ (PPARγ) is a member of a superfamily of nuclear transcription factors activated by agonists and is a promising therapeutic target for ameliorating IRI. Therefore, this review focuses on the role of PPARγ in IRI. The protective effects of PPARγ, such as attenuating oxidative stress, inhibiting inflammatory responses, and antagonizing apoptosis, are described, envisaging certain therapeutic perspectives.
Keywords: Mechanisms; PPARγ; Protective effect; Therapeutic potential; ischemia-reperfusion injury.
Copyright © 2021 Huang, Zhang, Wang and Hu.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures

Similar articles
-
Novel Targets and Therapeutic Strategies to Protect Against Hepatic Ischemia Reperfusion Injury.Front Med (Lausanne). 2022 Jan 4;8:757336. doi: 10.3389/fmed.2021.757336. eCollection 2021. Front Med (Lausanne). 2022. PMID: 35059411 Free PMC article. Review.
-
The Role of Peroxisome Proliferator-Activated Receptor γ in Mediating Cardioprotection Against Ischemia/Reperfusion Injury.J Cardiovasc Pharmacol Ther. 2018 Jan;23(1):46-56. doi: 10.1177/1074248417707049. Epub 2017 May 3. J Cardiovasc Pharmacol Ther. 2018. PMID: 28466688 Review.
-
Peroxisome proliferator-activated receptor γ (PPARγ) mediates the protective effect of quercetin against myocardial ischemia-reperfusion injury via suppressing the NF-κB pathway.Am J Transl Res. 2016 Dec 15;8(12):5169-5186. eCollection 2016. Am J Transl Res. 2016. PMID: 28077993 Free PMC article.
-
Calycosin attenuates renal ischemia/reperfusion injury by suppressing NF-κB mediated inflammation via PPARγ/EGR1 pathway.Front Pharmacol. 2022 Oct 7;13:970616. doi: 10.3389/fphar.2022.970616. eCollection 2022. Front Pharmacol. 2022. PMID: 36278223 Free PMC article.
-
Novel Targets for Treating Ischemia-Reperfusion Injury in the Liver.Int J Mol Sci. 2018 Apr 26;19(5):1302. doi: 10.3390/ijms19051302. Int J Mol Sci. 2018. PMID: 29701719 Free PMC article. Review.
Cited by
-
Adjuvant therapies for management of hemorrhagic shock: a narrative review.Crit Care. 2025 Mar 29;29(1):138. doi: 10.1186/s13054-025-05368-w. Crit Care. 2025. PMID: 40158128 Free PMC article.
-
An Overview of the Role of Peroxisome Proliferator-activated Receptors in Liver Diseases.J Clin Transl Hepatol. 2023 Dec 28;11(7):1542-1552. doi: 10.14218/JCTH.2023.00334. Epub 2023 Nov 15. J Clin Transl Hepatol. 2023. PMID: 38161499 Free PMC article. Review.
-
Two steps, one ligand: How PPARγ binds small-molecule agonists.Structure. 2021 Sep 2;29(9):935-936. doi: 10.1016/j.str.2021.08.005. Structure. 2021. PMID: 34478635 Free PMC article.
-
Cardiomyopeptide-Regulated PPARγ Expression Plays a Critical Role in Maintaining Mitochondrial Integrity and Preventing Cardiac Ischemia/Reperfusion Injury.Int J Med Sci. 2025 Jan 1;22(1):44-52. doi: 10.7150/ijms.102763. eCollection 2025. Int J Med Sci. 2025. PMID: 39744161 Free PMC article.
-
Pretreatment with a modified St. Thomas' solution in patients with severe upper limb injuries: Four case reports.World J Clin Cases. 2023 Jul 16;11(20):4926-4931. doi: 10.12998/wjcc.v11.i20.4926. World J Clin Cases. 2023. PMID: 37583986 Free PMC article.
References
-
- Aronoff S., Rosenblatt S., Braithwaite S., Egan J. W., Mathisen A. L., Schneider R. L. (2000). Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group. Diabetes Care 23, 1605–1611. 10.2337/diacare.23.11.1605 - DOI - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources